6
Participants
Start Date
August 2, 2022
Primary Completion Date
December 3, 2024
Study Completion Date
June 30, 2027
Pembrolizumab
200 mg IV every 3 weeks for a maximum of 2 years.
Lenvatinib
20 mg daily for a maximum of 2 years.
Providence Portland Medical Center, Portland
Merck Sharp & Dohme LLC
INDUSTRY
Eisai Inc.
INDUSTRY
Providence Health & Services
OTHER